Table 1 Baseline characteristics of subjects with steady-state bronchiectasis and healthy controls
| Â | Bronchiectasis | Controls | P values |
|---|---|---|---|
Age, y | 51.0 ± 13.9 | 49.5 ± 11.9 | 0.47 |
Male sex, No. (%) | 22 (27.5) | 22 (27.5) | 1.00 |
Body-mass index, kg/m2 | 20.5 ± 2.0 | 25.2 ± 3.6 | < 0.001 |
Current smoking, No. (%) | 12 (15.0%) | 18 (22.5%) | 0.22 |
SBP, mmHg | 120.9 ± 9.6 | 117.6 ± 11.2 | 0.62 |
DBP, mmHg | 81.6 ± 8.6 | 73.4 ± 10.5 | 0.34 |
HR, bpm | 82.6 ± 5.3 | 80.1 ± 4.2 | 0.001 |
Spirometry | |||
 FVC% predicted | 82.3 ± 16.7 | – | – |
 FEV1% predicted | 67.3 ± 21.4 | – | – |
mMRC grade | 1.0 (0–2.0) | – | – |
Exacerbation frequency in the past 12 mo | 2.0 (1.3–5.0) | – | – |
Hospital admission in the past 24 mo | 2.0 (1.0–3.0) | – | – |
Modiffied Reiff score for chest HRCT scan | 5.0 (2.0–10.0) | – | – |
PA colonization, No. (%) | 17 (21.3%) | – | – |
Aetiology | |||
 Idiopathic, No. (%) | 26 (32.5%) | – | – |
 Post infective, No. (%) | 25 (31.3%) | – | – |
 COPD, No. (%) | 14 (17.5%) | – | – |
 Asthma, No. (%) | 5 (6.3%) | – | – |
 Othersa, No. (%) | 10 (12.5%) | – | – |
BSI Scores | |||
 Mild (0–4), No. (%) | 27 (33.8%) | – | – |
 Moderate (5–8), No. (%) | 11 (13.8%) | – | – |
 Severe (≥9), No. (%) | 42 (52.5%) | – | – |
Comorbidities | |||
 Hypertension, No. (%) | 1 (1.3%) | 2 (2.5%) | 0.56 |
 Diabetes, No. (%) | 6 (7.5%) | 3 (3.8%) | 0.30 |
 Coronary heart disease, No. (%) | 3 (3.8%) | 3 (3.8%) | 1.00 |
 Stroke, No. (%) | 0 (0%) | 0 (0%) | … |
 Peripheral arterial disease, No. (%) | 0 (0%) | 0 (0%) | … |
Clinical chemistry | |||
 Cholesterol, mmol/L | 3.8 ± 1.1 | – | – |
 Triglyceride, mmol/L | 1.0 ± 0.7 | – | – |
 LDL-C, mmol/L | 2.2 (1.9–2.4) | – | – |
 HDL-C, mmol/L | 1.9 (1.0–1.4) | – | – |
Systemic inflammatory markers | |||
 IL-6, pg/mL | 3.3 (1.8–7.9) | – | – |
 IL-8, pg/mL | 7.1 (4.3–11.8) | – | – |
 C-reactive protein, mg/dL | 1.17 (0.3–3.9) | – | – |
 Fibrinogen, g/L | 3.2 ± 0.9 | – | – |